JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States. Cancer Res. 2023 Jan 18; 83(2):264-284.
View in:
PubMed
Breast cancer prevention by short-term inhibition of TGFß signaling. Nat Commun. 2022 12 07; 13(1):7558.
View in:
PubMed
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts. Cancer Cell. 2022 12 12; 40(12):1521-1536.e7.
View in:
PubMed
Untangling the web of intratumour heterogeneity. Nat Cell Biol. 2022 08; 24(8):1192-1201.
View in:
PubMed
Bacterial Darth Vader: May the force be with you. Cancer Cell. 2022 06 13; 40(6):600-602.
View in:
PubMed
Report of the First International Symposium on NUT Carcinoma. Clin Cancer Res. 2022 06 13; 28(12):2493-2505.
View in:
PubMed
Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer. Cancer Immunol Res. 2022 06 03; 10(6):680-697.
View in:
PubMed
Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress. Proc Natl Acad Sci U S A. 2022 01 18; 119(3).
View in:
PubMed
A Darwinian perspective on tumor immune evasion. Biochim Biophys Acta Rev Cancer. 2022 01; 1877(1):188671.
View in:
PubMed
The MCF10 Model of Breast Tumor Progression. Cancer Res. 2021 08 15; 81(16):4183-4185.
View in:
PubMed
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer. JCI Insight. 2021 06 08; 6(11).
View in:
PubMed
Early-Life Body Adiposity and the Breast Tumor Transcriptome. J Natl Cancer Inst. 2021 06 01; 113(6):778-784.
View in:
PubMed
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discov. 2021 10; 11(10):2474-2487.
View in:
PubMed
Identifying key questions in the ecology and evolution of cancer. Evol Appl. 2021 Apr; 14(4):877-892.
View in:
PubMed
Genomic Alterations during the In Situ to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System. Mol Cancer Res. 2021 04; 19(4):623-635.
View in:
PubMed
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. Sci Adv. 2020 06; 6(25):eabb2210.
View in:
PubMed
Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Mol Cell. 2020 06 18; 78(6):1096-1113.e8.
View in:
PubMed
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. Nat Commun. 2020 05 11; 11(1):2350.
View in:
PubMed
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. Cancer Cell. 2020 04 13; 37(4):471-484.
View in:
PubMed
Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Case-Control Analysis Nested within the Nurses' Health Study II. Cancer Epidemiol Biomarkers Prev. 2020 06; 29(6):1264-1270.
View in:
PubMed
Immune Escape during Breast Tumor Progression. Cancer Immunol Res. 2020 04; 8(4):422-427.
View in:
PubMed
A roadmap for the next decade in cancer research. Nat Cancer. 2020 01; 1(1):12-17.
View in:
PubMed
Tumor Neoantigens: When Too Much of a Good Thing Is Bad. Cancer Cell. 2019 11 11; 36(5):466-467.
View in:
PubMed
Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ. Nat Commun. 2019 09 13; 10(1):4182.
View in:
PubMed
Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. Nat Cell Biol. 2019 07; 21(7):879-888.
View in:
PubMed
EN1 Is a Transcriptional Dependency in Triple-Negative Breast Cancer Associated with Brain Metastasis. Cancer Res. 2019 08 15; 79(16):4173-4183.
View in:
PubMed
Metastasis as a systemic disease: molecular insights and clinical implications. Biochim Biophys Acta Rev Cancer. 2019 08; 1872(1):89-102.
View in:
PubMed
Intratumoral Heterogeneity: More Than Just Mutations. Trends Cell Biol. 2019 07; 29(7):569-579.
View in:
PubMed
Deletion of Cdkn1b in ACI rats leads to increased proliferation and pregnancy-associated changes in the mammary gland due to perturbed systemic endocrine environment. PLoS Genet. 2019 03; 15(3):e1008002.
View in:
PubMed
KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell. 2019 Feb 11; 35(2):330-332.
View in:
PubMed
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019 02; 9(2):176-198.
View in:
PubMed
Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS). JNCI Cancer Spectr. 2018 Nov; 2(4):pky063.
View in:
PubMed
KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell. 2018 12 10; 34(6):939-953.e9.
View in:
PubMed
TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer. Cell Rep. 2018 10 30; 25(5):1255-1267.e5.
View in:
PubMed
Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors. Mol Oncol. 2018 11; 12(11):1838-1855.
View in:
PubMed
Dissecting the mammary gland one cell at a time. Nat Commun. 2018 06 26; 9(1):2473.
View in:
PubMed
A confetti trail of tumour evolution. Nat Cell Biol. 2018 06; 20(6):639-641.
View in:
PubMed
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer. 2018; 4:10.
View in:
PubMed
Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion. J Pathol. 2017 12; 243(4):496-509.
View in:
PubMed
Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference. J Cancer. 2017; 8(17):3607-3614.
View in:
PubMed
Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer. 2017 10; 17(10):605-619.
View in:
PubMed
Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer Discov. 2017 10; 7(10):1098-1115.
View in:
PubMed
The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. Nature. 2017 06 15; 546(7658):426-430.
View in:
PubMed
Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. Cancer Cell. 2017 04 10; 31(4):576-590.e8.
View in:
PubMed
Precancer Atlas to Drive Precision Prevention Trials. Cancer Res. 2017 04 01; 77(7):1510-1541.
View in:
PubMed
Mathematical Modeling Links Pregnancy-Associated Changes and Breast Cancer Risk. Cancer Res. 2017 06 01; 77(11):2800-2809.
View in:
PubMed
G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells. Nat Cell Biol. 2017 03; 19(3):177-188.
View in:
PubMed
BET Bromodomain Proteins as Cancer Therapeutic Targets. Cold Spring Harb Symp Quant Biol. 2016; 81:123-129.
View in:
PubMed
Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer. NPJ Breast Cancer. 2016; 2.
View in:
PubMed
Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Res. 2016 11 15; 76(22):6495-6506.
View in:
PubMed
Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer. Cell Rep. 2016 08 16; 16(7):2032-46.
View in:
PubMed
BRCA1/FANCD2/BRG1-Driven DNA Repair Stabilizes the Differentiation State of Human Mammary Epithelial Cells. Mol Cell. 2016 07 21; 63(2):277-292.
View in:
PubMed
The Proliferative Activity of Mammary Epithelial Cells in Normal Tissue Predicts Breast Cancer Risk in Premenopausal Women. Cancer Res. 2016 04 01; 76(7):1926-34.
View in:
PubMed
Voices of biotech. Nat Biotechnol. 2016 Mar; 34(3):270-5.
View in:
PubMed
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016 Jan 21; 529(7586):413-417.
View in:
PubMed
Intratumor Heterogeneity in Breast Cancer. Adv Exp Med Biol. 2016; 882:169-89.
View in:
PubMed
Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome. Cell Rep. 2015 Oct 13; 13(2):277-89.
View in:
PubMed
Combining miR-10b-Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer. Cancer Res. 2015 Oct 15; 75(20):4407-15.
View in:
PubMed
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet. 2015 Oct; 47(10):1212-9.
View in:
PubMed
Toward understanding and exploiting tumor heterogeneity. Nat Med. 2015 Aug; 21(8):846-53.
View in:
PubMed
HOXB7 Is an ERa Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance. Cancer Discov. 2015 Sep; 5(9):944-59.
View in:
PubMed
Tumorigenesis: it takes a village. Nat Rev Cancer. 2015 Aug; 15(8):473-83.
View in:
PubMed
Somatic Cell Fusions Reveal Extensive Heterogeneity in Basal-like Breast Cancer. Cell Rep. 2015 Jun 16; 11(10):1549-63.
View in:
PubMed
Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling. BMC Cancer. 2015 Feb 19; 15:70.
View in:
PubMed
CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer. Cancer Res. 2015 Apr 01; 75(7):1516-26.
View in:
PubMed
Age- and pregnancy-associated DNA methylation changes in mammary epithelial cells. Stem Cell Reports. 2015 Feb 10; 4(2):297-311.
View in:
PubMed
Clonal evolution in cancer: a tale of twisted twines. Cell Stem Cell. 2015 Jan 08; 16(1):11-2.
View in:
PubMed
BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nat Commun. 2014 Nov 17; 5:5496.
View in:
PubMed
MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis. Cell Stem Cell. 2014 Dec 04; 15(6):762-74.
View in:
PubMed
Tumor heterogeneity: the Lernaean hydra of oncology? Oncology (Williston Park). 2014 Sep; 28(9):781-2, 784.
View in:
PubMed
Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature. 2014 Oct 02; 514(7520):54-8.
View in:
PubMed
JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell. 2014 Jun 16; 25(6):762-77.
View in:
PubMed
Histone demethylase jumonji AT-rich interactive domain 1B (JARID1B) controls mammary gland development by regulating key developmental and lineage specification genes. J Biol Chem. 2014 Jun 20; 289(25):17620-33.
View in:
PubMed
Oncogene-like induction of cellular invasion from centrosome amplification. Nature. 2014 Jun 05; 510(7503):167-71.
View in:
PubMed
Cancer: Clonal cooperation. Nature. 2014 Apr 03; 508(7494):52-3.
View in:
PubMed
Tumor heterogeneity confounds and illuminates: a case for Darwinian tumor evolution. Nat Med. 2014 Apr; 20(4):344-6.
View in:
PubMed
Sorting out the FACS: a devil in the details. Cell Rep. 2014 Mar 13; 6(5):779-81.
View in:
PubMed
Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep. 2014 Feb 13; 6(3):514-27.
View in:
PubMed
Genetic and phenotypic diversity in breast tumor metastases. Cancer Res. 2014 Mar 01; 74(5):1338-48.
View in:
PubMed
Targeting Akt3 signaling in triple-negative breast cancer. Cancer Res. 2014 Feb 01; 74(3):964-73.
View in:
PubMed
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013 Oct 14; 24(4):450-65.
View in:
PubMed
The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell. 2013 Sep 09; 24(3):365-78.
View in:
PubMed
Methylation-specific digital karyotyping of HPV16E6E7-expressing human keratinocytes identifies novel methylation events in cervical carcinogenesis. J Pathol. 2013 Sep; 231(1):53-62.
View in:
PubMed
Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. Cell Stem Cell. 2013 Jul 03; 13(1):117-30.
View in:
PubMed
Tracking tumor resistance using 'liquid biopsies'. Nat Med. 2013 Jun; 19(6):676-7.
View in:
PubMed
Deconvoluting complex tissues for expression quantitative trait locus-based analyses. Philos Trans R Soc Lond B Biol Sci. 2013; 368(1620):20120363.
View in:
PubMed
Cancer. Cancer cell phenotypes, in fifty shades of grey. Science. 2013 Feb 01; 339(6119):528-9.
View in:
PubMed
RNA sequencing of cancer reveals novel splicing alterations. Sci Rep. 2013; 3:1689.
View in:
PubMed
The expression of Psoriasin (S100A7) and CD24 is linked and related to the differentiation of mammary epithelial cells. PLoS One. 2012; 7(12):e53119.
View in:
PubMed
A blueprint for an international cancer epigenome consortium. A report from the AACR Cancer Epigenome Task Force. Cancer Res. 2012 Dec 15; 72(24):6319-24.
View in:
PubMed
Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol. 2013 Jan 24; 8:277-302.
View in:
PubMed
SnapShot: breast cancer. Cancer Cell. 2012 Oct 16; 22(4):562-562.e1.
View in:
PubMed
The challenges posed by cancer heterogeneity. Nat Biotechnol. 2012 Jul 10; 30(7):604-10.
View in:
PubMed
On using functional genetics to understand breast cancer biology. Cold Spring Harb Perspect Biol. 2012 Jul 01; 4(7):a013516.
View in:
PubMed
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012 Jun 20; 486(7403):405-9.
View in:
PubMed
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012 Apr 19; 12(5):323-34.
View in:
PubMed
Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov. 2012 Jun; 2(6):503-11.
View in:
PubMed
On chromatin remodeling in mammary gland differentiation and breast tumorigenesis. Cold Spring Harb Perspect Biol. 2012 Mar 01; 4(3).
View in:
PubMed
Progress in breast cancer research. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2715-7.
View in:
PubMed
Somatic mutations in the Notch, NF-KB, PIK3CA, and Hedgehog pathways in human breast cancers. Genes Chromosomes Cancer. 2012 May; 51(5):480-9.
View in:
PubMed
The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proc Natl Acad Sci U S A. 2012 Jan 03; 109(1):221-6.
View in:
PubMed
PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene. 2012 Jul 19; 31(29):3397-408.
View in:
PubMed
The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res. 2011; 13(6):227.
View in:
PubMed
Heterogeneity in breast cancer. J Clin Invest. 2011 Oct; 121(10):3786-8.
View in:
PubMed
Unraveling the complexity of basal-like breast cancer. Oncotarget. 2011 Aug; 2(8):588-9.
View in:
PubMed
The JAK2/STAT3 signaling pathway is required for growth of CD44?CD24? stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011 Jul; 121(7):2723-35.
View in:
PubMed
Epigenetic regulation of cell type-specific expression patterns in the human mammary epithelium. PLoS Genet. 2011 Apr; 7(4):e1001369.
View in:
PubMed
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A. 2011 May 10; 108(19):7950-5.
View in:
PubMed
Functional synergies yet distinct modulators affected by genetic alterations in common human cancers. Cancer Res. 2011 May 15; 71(10):3471-81.
View in:
PubMed
Targeting the missing links for cancer therapy. Nat Med. 2011 Mar; 17(3):283-4.
View in:
PubMed
Altered antisense-to-sense transcript ratios in breast cancer. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2820-4.
View in:
PubMed
Gene expression profiling of human breast tissue samples using SAGE-Seq. Genome Res. 2010 Dec; 20(12):1730-9.
View in:
PubMed
The origins and implications of intratumor heterogeneity. Cancer Prev Res (Phila). 2010 Nov; 3(11):1361-4.
View in:
PubMed
Going small is the new big. Nat Methods. 2010 Aug; 7(8):597, 599-600.
View in:
PubMed
PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One. 2010 Jul 23; 5(7):e11729.
View in:
PubMed
The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol. 2010 Nov; 2(11):a003244.
View in:
PubMed
PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res. 2010 Jul 15; 70(14):5674-8.
View in:
PubMed
Stem cells in the human breast. Cold Spring Harb Perspect Biol. 2010 May; 2(5):a003160.
View in:
PubMed
Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res. 2010 Feb 01; 16(3):876-87.
View in:
PubMed
Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. Oncogene. 2010 Apr 22; 29(16):2337-45.
View in:
PubMed
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest. 2010 Feb; 120(2):636-44.
View in:
PubMed
Molecular markers for the diagnosis and management of ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010; 2010(41):210-3.
View in:
PubMed
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009 Nov 18; 4(11):e7887.
View in:
PubMed
Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010 Jan; 1805(1):105-17.
View in:
PubMed
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell. 2009 Nov 06; 16(5):413-24.
View in:
PubMed
Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution. Cancer Res. 2009 Sep 01; 69(17):6765-8; discussion 6769.
View in:
PubMed
Identification of CD44v6(+)/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies. Lab Invest. 2009 Aug; 89(8):857-66.
View in:
PubMed
Epigenetic patterns of embryonic and adult stem cells. Cell Cycle. 2009 Mar 15; 8(6):809-17.
View in:
PubMed
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009 Apr; 9(4):265-73.
View in:
PubMed
Origin of carcinoma associated fibroblasts. Cell Cycle. 2009 Feb 15; 8(4):589-95.
View in:
PubMed
Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci U S A. 2009 Mar 03; 106(9):3372-7.
View in:
PubMed
Cancer stem cells: a model in the making. Curr Opin Genet Dev. 2009 Feb; 19(1):44-50.
View in:
PubMed
An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res. 2009; 11(5):R66.
View in:
PubMed
Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009 Jan; 25(1):30-8.
View in:
PubMed
Molecular characterisation of the tumour microenvironment in breast cancer. Eur J Cancer. 2008 Dec; 44(18):2760-5.
View in:
PubMed
Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res. 2008 Nov 15; 68(22):9532-40.
View in:
PubMed
Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9. Breast Cancer Res. 2008; 10(5):R91.
View in:
PubMed
Detection of psoriasin/S100A7 in the sera of patients with psoriasis. Br J Dermatol. 2009 Feb; 160(2):325-32.
View in:
PubMed
Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A. 2008 Sep 16; 105(37):14076-81.
View in:
PubMed
Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res. 2008 Sep 01; 14(17):5357-67.
View in:
PubMed
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008 May 16; 133(4):704-15.
View in:
PubMed
Regulation of in situ to invasive breast carcinoma transition. Cancer Cell. 2008 May; 13(5):394-406.
View in:
PubMed
No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet. 2008 May; 40(5):650-5.
View in:
PubMed
Breast-cancer stromal cells with TP53 mutations. N Engl J Med. 2008 Apr 10; 358(15):1634-5; author reply 1636.
View in:
PubMed
The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest. 2008 May; 88(5):459-63.
View in:
PubMed
S100A7-downregulation inhibits epidermal growth factor-induced signaling in breast cancer cells and blocks osteoclast formation. PLoS One. 2008 Mar 05; 3(3):e1741.
View in:
PubMed
Microenvironmental regulation of cancer development. Curr Opin Genet Dev. 2008 Feb; 18(1):27-34.
View in:
PubMed
Cyclooxygenase-2 expression during immortalization and breast cancer progression. Cancer Res. 2008 Jan 15; 68(2):467-75.
View in:
PubMed
Is breast tumor progression really linear? Clin Cancer Res. 2008 Jan 15; 14(2):339-41.
View in:
PubMed
Breast cancer: origins and evolution. J Clin Invest. 2007 Nov; 117(11):3155-63.
View in:
PubMed
The genomic landscapes of human breast and colorectal cancers. Science. 2007 Nov 16; 318(5853):1108-13.
View in:
PubMed
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007 Oct 04; 449(7162):557-63.
View in:
PubMed
Serial analysis of gene expression (SAGE): experimental method and data analysis. Curr Protoc Mol Biol. 2007 Oct; Chapter 25:Unit 25B.6.
View in:
PubMed
Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle. 2007 Oct 01; 6(19):2332-8.
View in:
PubMed
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007 Jun 15; 129(6):1065-79.
View in:
PubMed
Breast cancer stem cells: a case of mistaken identity? Stem Cell Rev. 2007 Jun; 3(2):107-9.
View in:
PubMed
Serial analysis of gene expression (SAGE): experimental method and data analysis. Curr Protoc Hum Genet. 2007 Apr; Chapter 11:Unit 11.7.
View in:
PubMed
Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007 Mar; 11(3):259-73.
View in:
PubMed
The p27Kip1 tumor suppressor gene: Still a suspect or proven guilty? Cancer Cell. 2006 Nov; 10(5):352-4.
View in:
PubMed
Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res. 2006 Apr 15; 66(8):4065-78.
View in:
PubMed
Pregnancy and breast cancer: the other side of the coin. Cancer Cell. 2006 Mar; 9(3):151-3.
View in:
PubMed
Roots and stems: stem cells in cancer. Nat Med. 2006 Mar; 12(3):296-300.
View in:
PubMed
SAGE and related approaches for cancer target identification. Drug Discov Today. 2006 Feb; 11(3-4):110-8.
View in:
PubMed
Methylation-specific digital karyotyping. Nat Protoc. 2006; 1(3):1621-36.
View in:
PubMed
Serial analysis of gene expression. Nat Protoc. 2006; 1(4):1743-60.
View in:
PubMed
A putative role for psoriasin in breast tumor progression. Cancer Res. 2005 Dec 15; 65(24):11326-34.
View in:
PubMed
HIN-1, an inhibitor of cell growth, invasion, and AKT activation. Cancer Res. 2005 Nov 01; 65(21):9659-69.
View in:
PubMed
Psoriasin (S100A7) and calgranulin-B (S100A9) induction is dependent on reactive oxygen species and is downregulated by Bcl-2 and antioxidants. Cancer Biol Ther. 2005 Sep; 4(9):998-1005.
View in:
PubMed
Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet. 2005 Aug; 37(8):899-905.
View in:
PubMed
Do myoepithelial cells hold the key for breast tumor progression? J Mammary Gland Biol Neoplasia. 2005 Jul; 10(3):231-47.
View in:
PubMed
Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med. 2005 Mar; 11(3):261-2.
View in:
PubMed
Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res. 2004 Sep; 2(9):489-94.
View in:
PubMed
Cancer chromosomes in crisis. Nat Genet. 2004 Sep; 36(9):932-4.
View in:
PubMed
EMSY links breast cancer gene 2 to the 'Royal Family'. Breast Cancer Res. 2004; 6(5):201-3.
View in:
PubMed
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004 Jul; 6(1):17-32.
View in:
PubMed
Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res. 2004 May 01; 10(9):3104-9.
View in:
PubMed
Ductal carcinoma in situ of the breast. N Engl J Med. 2004 Apr 01; 350(14):1430-41.
View in:
PubMed
Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res. 2004 Mar 15; 10(6):2052-7.
View in:
PubMed
DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer. 2003 Dec 20; 107(6):970-5.
View in:
PubMed
Cancer target discovery using SAGE. Expert Opin Ther Targets. 2003 Dec; 7(6):759-69.
View in:
PubMed
A neural survival factor is a candidate oncogene in breast cancer. Proc Natl Acad Sci U S A. 2003 Sep 16; 100(19):10931-6.
View in:
PubMed
The hairy powers of oncogenes: from biological function to cancer therapy. Cancer Biol Ther. 2003 Sep-Oct; 2(5):592-4.
View in:
PubMed
Identifying tumor origin using a gene expression-based classification map. Cancer Res. 2003 Jul 15; 63(14):4144-9.
View in:
PubMed
Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors. Cancer Res. 2003 May 01; 63(9):2024-7.
View in:
PubMed
Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res. 2003 Mar; 1(5):362-75.
View in:
PubMed
Breast cancer gene discovery. Expert Rev Mol Med. 2002 Aug 15; 4(18):1-18.
View in:
PubMed
Cellular and molecular targets of estrogen in normal human breast tissue. Cancer Res. 2002 Aug 15; 62(16):4540-4.
View in:
PubMed
An anatomy of normal and malignant gene expression. Proc Natl Acad Sci U S A. 2002 Aug 20; 99(17):11287-92.
View in:
PubMed
Expression of high in normal-1 (HIN-1) and uteroglobin related protein-1 (UGRP-1) in adult and developing tissues. Mech Dev. 2002 Jun; 114(1-2):201-4.
View in:
PubMed
Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression). Oncogene. 2002 Jan 24; 21(5):836-43.
View in:
PubMed
Molecular alterations in ductal carcinoma in situ of the breast. Curr Opin Oncol. 2002 Jan; 14(1):92-6.
View in:
PubMed
Is p53 a breast cancer gene? Cancer Biol Ther. 2002 Jan-Feb; 1(1):37-8.
View in:
PubMed
Psoriasin expression in mammary epithelial cells in vitro and in vivo. Cancer Res. 2002 Jan 01; 62(1):43-7.
View in:
PubMed
On the birth of breast cancer. Biochim Biophys Acta. 2001 Nov 30; 1552(1):1-13.
View in:
PubMed
A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res. 2001 Aug 01; 61(15):5697-702.
View in:
PubMed
HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci U S A. 2001 Aug 14; 98(17):9796-801.
View in:
PubMed
Gene discovery using the serial analysis of gene expression technique: implications for cancer research. J Clin Oncol. 2001 Jun 01; 19(11):2948-58.
View in:
PubMed
Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. Cancer Res. 2000 Dec 15; 60(24):6859-63.
View in:
PubMed
p53-dependent expression of PIG3 during proliferation, genotoxic stress, and reversible growth arrest. Cancer Lett. 2000 Aug 01; 156(1):63-72.
View in:
PubMed
Analysis of human transcriptomes. Nat Genet. 1999 Dec; 23(4):387-8.
View in:
PubMed
A public database for gene expression in human cancers. Cancer Res. 1999 Nov 01; 59(21):5403-7.
View in:
PubMed
CDX2 is mutated in a colorectal cancer with normal APC/beta-catenin signaling. Oncogene. 1999 Sep 02; 18(35):5010-4.
View in:
PubMed
Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet. 1998 Nov; 20(3):291-3.
View in:
PubMed
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998 Jun 09; 95(12):6870-5.
View in:
PubMed
14-3-3sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell. 1997 Dec; 1(1):3-11.
View in:
PubMed
A model for p53-induced apoptosis. Nature. 1997 Sep 18; 389(6648):300-5.
View in:
PubMed
Less death in the dying. Cell Death Differ. 1997 Apr; 4(3):242-6.
View in:
PubMed
Early alteration of cell-cycle-regulated gene expression in colorectal neoplasia. Am J Pathol. 1996 Aug; 149(2):381-7.
View in:
PubMed
Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 1996 Aug 01; 10(15):1945-52.
View in:
PubMed
A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell. 1996 May 31; 85(5):733-44.
View in:
PubMed
Negative regulation of cell growth by TGF beta. Biochim Biophys Acta. 1996 Mar 18; 1242(3):185-99.
View in:
PubMed
Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissues. Cancer Res. 1996 Jan 15; 56(2):235-40.
View in:
PubMed
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev. 1995 Aug 01; 9(15):1831-45.
View in:
PubMed
Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature. 1995 Jul 27; 376(6538):313-20.
View in:
PubMed
p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res. 1995 Mar 15; 55(6):1211-4.
View in:
PubMed
Mammalian antiproliferative signals and their targets. Curr Opin Genet Dev. 1995 Feb; 5(1):91-6.
View in:
PubMed
p27KIP1, an inhibitor of cyclin-dependent kinases. Prog Cell Cycle Res. 1995; 1:141-7.
View in:
PubMed
Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 1994 Dec 08; 372(6506):570-3.
View in:
PubMed
Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell. 1994 Nov 04; 79(3):487-96.
View in:
PubMed
Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994 Jul 15; 78(1):59-66.
View in:
PubMed
Cyclins, Cdks, and cyclin kinase inhibitors. Cold Spring Harb Symp Quant Biol. 1994; 59:31-8.
View in:
PubMed
p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 1994 Jan; 8(1):9-22.
View in:
PubMed
Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. Science. 1993 Apr 23; 260(5107):536-9.
View in:
PubMed